HIROMI CHAYAMA

Last Updated :2024/07/03

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Medicine), Associate Professor
E-mail
habehiroshima-u.ac.jp
Self-introduction
I am interested in the life cycles of the hepatitis viruses and the immune responses of the host to the hepatitis viruses. The goal of my research is to elucidate the intracellular dynamics and immune responses of the hepatitis viruses and to develop novel therapeutic agents that can completely eliminate the hepatitis virus from infected cells.

Basic Information

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Research Fields

  • Engineering;Process / Chemical engineering;Biofunction / Bioprocess
  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Gastroenterology

Educational Activity

Course in Charge

  1. 2024, Graduate Education (Master's Program) , 1Term, Start-Up Coursework of Biomedical Sciences
  2. 2024, Graduate Education (Master's Program) , 3Term, Start-Up Coursework of Biomedical Sciences
  3. 2024, Graduate Education (Doctoral Program) , 3Term, Advanced Coursework of Biomedical Sciences

Research Activities

Academic Papers

  1. HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice, HEPATOLOGY, 78(3), 929-942, 202309
  2. Deficiency of SCAP inhibits HBV pathogenesis via activation of the interferon signaling pathway, VIROLOGY, 585, 248-258, 202308
  3. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL, JOURNAL OF INFECTIOUS DISEASES, 227(5), 686-695, 20230301
  4. A novel cDNA-uPA/SCID/Rag2(-/-)/Jak3(-/-) mouse model for hepatitis virus infection and reconstruction of human immune system, JOURNAL OF VIRAL HEPATITIS, 30(3), 262-272, 202303
  5. Untying relaxed circular DNA of hepatitis B virus by polymerase reaction provides a new option for accurate quantification and visualization of covalently closed circular DNA, JOURNAL OF GENERAL VIROLOGY, 103(2), 2022
  6. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84(3), 391-399, 202203
  7. Identification of novel HCV deletion mutants in chronic hepatitis C patients, ANTIVIRAL THERAPY, 17(8), 1551-1561, 2012
  8. Toward the Establishment of a Prediction System for the Personalized Treatment of Chronic Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 205(2), 204-210, 2012
  9. Serum PAI-1 is a novel predictor for response to pegylated interferon-a-2b plus ribavirin therapy in chronic hepatitis C virus infection, JOURNAL OF VIRAL HEPATITIS, 19(2), E126-E133, 201202
  10. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse, HEPATOLOGY, 56(2), 555-566, 201208
  11. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, JOURNAL OF GASTROENTEROLOGY, 47(7), 834-844, 201207
  12. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 7(10), 2012
  13. Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C, JOURNAL OF GENERAL VIROLOGY, 94, 81-89, 201301
  14. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B, JOURNAL OF MEDICAL VIROLOGY, 85(5), 789-798, 201301
  15. A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region, JOURNAL OF HEPATOLOGY, 58(5), 875-882, 201305
  16. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, GUT, 62(7), 1055-1061, 201307
  17. A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108(9), 1464-1472, 201309
  18. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, JOURNAL OF GASTROENTEROLOGY, 48(10), 1188-1204, 201310
  19. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441(1), 230-235, 2013
  20. Aryl hydrocarbon receptor plays protective roles in ConA-induced hepatic injury by both suppressing IFN- expression and inducing IL-22, INTERNATIONAL IMMUNOLOGY, 26(3), 129-137, 201405
  21. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir., J Hepatol., 58, 646-654, 20130501
  22. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice., J Infect Dis., 204, 224-228, 20110401
  23. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse., PLoS One., 6, e23856, 20110801
  24. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice., J Hepatol., 54, 872-878, 20110501
  25. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations., J Gen Virol., 92, 1071-1081, 20110801
  26. ★, Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers., Nat Genet., 43, 797-800, 20111001
  27. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population., Hum Mol Genet., 20, 3884-3892, 20110301
  28. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b., J Hepatol., 54, 408-414, 20110901
  29. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo., Hepatology., 54, 781-788, 20110901
  30. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus., Hepatology., 54, 764-771, 20110201
  31. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy., Gut., 60, 261-267, 20110101
  32. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., J Med Virol., 83, 981-988, 20110401
  33. A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients., J Hepatol., 54, 629-639, 20110101
  34. Animal model for study of human hepatitis viruses., J Gastroenterol Hepatol., 26, 13-18, 20110701
  35. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C., J Infect Dis., 204, 84-93, 20110601
  36. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy., J Med Virol., 83, 1048-1057, 20110701
  37. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo., J Hepatol., 55, 41596, 20110901
  38. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state., J Med Virol., 83, 1597-1607, 20110601
  39. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy., J Hepatol., 54, 1094-1101, 20110501
  40. G to A hypermutation of TT virus., Virus Res., 149, 211-216, 20100701
  41. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice., J Gen Virol., 91, 1854-1864, 20101001
  42. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients., Gastroenterology., 139, 1190-1197, 20100801
  43. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrob Agents Chemother., 54, 3205-3211, 20100401
  44. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy., Antivir Ther., 15, 1087-1097, 20100401
  45. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B., Antivir Ther., 15, 177-184, 20100901
  46. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients., J Hepatol., 53, 439-443, 20100501
  47. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C., Gastroenterology., 136, 1796-1805, 20090601
  48. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection., J Infect Dis., 199, 1599-1607, 20091201
  49. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice., J Hepatol., 51, 1046-1054, 20091201
  50. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection., Hepatol Res., 39, 1159-1168, 20090901
  51. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice., J Gen Virol., 89, 2108-2113, 20080101
  52. Successful treatment of an entecavir-resistant hepatitis B virus variant., J Med Virol., 79, 1811-1817, 20070201
  53. Dual effect of APOBEC3G on Hepatitis B virus., J Gen Virol., 88, 432-440, 20070501
  54. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon., FEBS Lett., 581, 1983-1987, 20070501
  55. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine., Hepatology., 45, 1179-1186, 20071101
  56. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif., Antimicrob Agents Chemother., 50, 3867-3874, 20061201
  57. Ultra deep sequencing study of HCV genotype 1 in chronic hepatitis patients treated with daclatasvir, peg-interferon and ribavirin, Antimicrob Agents Chemother, 20140101
  58. HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLoS One, 8(12), e84226, 20131201
  59. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, J Gastroenterol, 20131201
  60. Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B, ANTIVIRAL THERAPY, 15(2), 177-184, 2010
  61. G to A hypermutation of TT virus, VIRUS RESEARCH, 149(2), 211-216, 201005
  62. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 91, 1854-1864, 201007
  63. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 54(5), 872-878, 201105
  64. Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8), 3205-3211, 201008
  65. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients, JOURNAL OF HEPATOLOGY, 53(3), 439-443, 201009
  66. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy, ANTIVIRAL THERAPY, 15(8), 1087-1097, 2010
  67. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b, JOURNAL OF HEPATOLOGY, 54(3), 408-414, 201103
  68. A single nucleotide polymorphism in activated cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients, JOURNAL OF HEPATOLOGY, 54(4), 629-639, 201104
  69. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain from Wildtype Clone In Vivo, HEPATOLOGY, 54(3), 781-788, 201109
  70. Prediction of Response to Peginterferon-Alfa-2b Plus Ribavirin Therapy in Japanese Patients Infected With Hepatitis C Virus Genotype 1b, JOURNAL OF MEDICAL VIROLOGY, 83(6), 981-988, 201106
  71. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy, JOURNAL OF MEDICAL VIROLOGY, 83(6), 1048-1057, 201106
  72. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations, JOURNAL OF GENERAL VIROLOGY, 92, 1071-1081, 201105
  73. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy, JOURNAL OF HEPATOLOGY, 54(6), 1094-1101, 201106
  74. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo, JOURNAL OF HEPATOLOGY, 55(1), 11-18, 201107
  75. IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C, JOURNAL OF INFECTIOUS DISEASES, 204(1), 84-93, 2011
  76. Inverse Association of IL28B Genotype and Liver mRNA Expression of Genes Promoting or Suppressing Antiviral State, JOURNAL OF MEDICAL VIROLOGY, 83(9), 1597-1607, 201109
  77. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers, NATURE GENETICS, 43(8), 797-U108, 201108
  78. Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse, PLOS ONE, 6(8), 2011
  79. Impact of Viral Amino Acid Substitutions and Host Interleukin-28B Polymorphism on Replication and Susceptibility to Interferon of Hepatitis C Virus, HEPATOLOGY, 54(3), 764-771, 201109
  80. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population, HUMAN MOLECULAR GENETICS, 20(19), 3884-3892, 2011
  81. Spinal astrocytes contribute to the circadian oscillation of glutamine synthase, cyclooxygenase-1 and clock genes in the lumbar spinal cord of mice, NEUROCHEMISTRY INTERNATIONAL, 60(8), 817-826, 201206
  82. Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58(4), 2105-2112, 201404
  83. Aryl hydrocarbon receptor protects against bacterial infection by promoting macrophage survival and reactive oxygen species production, INTERNATIONAL IMMUNOLOGY, 26(4), 209-220, 201404
  84. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA, JOURNAL OF VIRAL HEPATITIS, 21(9), E89-E97, 201409
  85. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population, JOURNAL OF GENERAL VIROLOGY, 95, 1297-1306, 201406
  86. New Insight Into the Enhanced Effect of Pegylated Interferon-alpha, HEPATOLOGY, 60(4), 1435-1437, 201410
  87. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49(12), 1548-1556, 201412
  88. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 70(3), 273-287, 201503
  89. The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30(3), 619-627, 201503
  90. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22(2), 158-165, 201502
  91. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, JOURNAL OF VIRAL HEPATITIS, 22(2), 166-174, 201502
  92. Novel Robust in Vitro Hepatitis B Virus Infection Model Using Fresh Human Hepatocytes Isolated from Humanized Mice, AMERICAN JOURNAL OF PATHOLOGY, 185(5), 1275-1285, 201505
  93. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay, PLOS ONE, 10(6), 2015
  94. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy, ANTIVIRAL THERAPY, 20(4), 369-375, 2015
  95. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 63(3), 554-563, 201509
  96. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones, JOURNAL OF INFECTION, 72(1), 91-102, 201601
  97. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice, VIRUS RESEARCH, 213, 62-68, 2016
  98. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51(11), 1073-1080, 201611
  99. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus, GENES TO CELLS, 21(11), 1253-1262, 201611
  100. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice, ANTIVIRAL THERAPY, 21(4), 307-315, 2016
  101. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing, JOURNAL OF INFECTIOUS DISEASES, 214(11), 1687-1694, 2016
  102. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus, PLOS ONE, 12(3), 2017
  103. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(6), 201706
  104. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, JOURNAL OF GENERAL VIROLOGY, 98(5), 1040-1047, 201705
  105. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53(1), 107-118, 201801
  106. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53(2), 269-280, 201802
  107. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(9), 201709
  108. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 500(2), 152-157, 2018
  109. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, JOURNAL OF GENERAL VIROLOGY, 99(8), 1058-1065, 201808
  110. Effects of sesamin and capsaicin on the mRNA expressions of delta6 and delta5 desaturases in rat primary cultured hepatocytes., Journal of nutritional science and vitaminology, 49(6), 2003
  111. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif., Antimicrobial agents and chemotherapy, 50(11), 2006
  112. Dual effect of APOBEC3G on Hepatitis B virus., The Journal of general virology, 88(Pt 2), 2007
  113. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine., Hepatology (Baltimore, Md.), 45(5), 2007
  114. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon., FEBS letters, 581(10), 2007
  115. Successful treatment of an entecavir-resistant hepatitis B virus variant., Journal of medical virology, 79(12), 2007
  116. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice., The Journal of general virology, 89(Pt 9), 2008
  117. G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection., The Journal of infectious diseases, 199(11), 2009
  118. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice., Journal of hepatology, 51(6), 2009
  119. G to A hypermutation of TT virus., Virus research, 149(2), 2010
  120. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice., The Journal of general virology, 91(Pt 7), 2010
  121. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrobial agents and chemotherapy, 54(8), 2010
  122. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice., Journal of hepatology, 54(5), 2011
  123. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo., Journal of hepatology, 55(1), 2011
  124. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy., Antiviral therapy, 15(8), 2010
  125. Animal model for study of human hepatitis viruses., Journal of gastroenterology and hepatology, 26(1), 2011
  126. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., Journal of medical virology, 83(6), 2011
  127. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus., Hepatology (Baltimore, Md.), 54(3), 2011
  128. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo., Hepatology (Baltimore, Md.), 54(3), 2011
  129. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice., The Journal of infectious diseases, 204(2), 2011
  130. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse., PloS one, 6(8), 2011
  131. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse., Hepatology (Baltimore, Md.), 56(2), 2012
  132. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients., Journal of gastroenterology, 47(7), 2012
  133. Spinal astrocytes contribute to the circadian oscillation of glutamine synthase, cyclooxygenase-1 and clock genes in the lumbar spinal cord of mice., Neurochemistry international, 60(8), 2012
  134. Identification of novel HCV deletion mutants in chronic hepatitis C patients., Antiviral therapy, 17(8), 2012
  135. Hepatitis B virus-specific miRNAs and Argonaute2 play a role in the viral life cycle., PloS one, 7(10), 2012
  136. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice., Gut, 62(7), 2013
  137. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients., Journal of gastroenterology, 48(10), 2013
  138. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B., Journal of medical virology, 85(5), 2013
  139. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing., The American journal of gastroenterology, 108(9), 2013
  140. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections., Biochemical and biophysical research communications, 441(1), 2013
  141. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C., Journal of gastroenterology, 49(12), 2014
  142. HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association study., PloS one, 8(12), 2013
  143. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin., Antimicrobial agents and chemotherapy, 58(4), 2014
  144. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population., The Journal of general virology, 95(Pt 6), 2014
  145. New insight into the enhanced effect of pegylated interferon-α., Hepatology (Baltimore, Md.), 60(4), 2014
  146. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway., Journal of gastroenterology and hepatology, 30(3), 2015
  147. Differences in serum microRNA profiles in hepatitis B and C virus infection., The Journal of infection, 70(3), 2015
  148. Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice., The American journal of pathology, 185(5), 2015
  149. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A., Journal of hepatology, 63(3), 2015
  150. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy., Journal of medical virology, 87(11), 2015
  151. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay., PloS one, 10(6), 2015
  152. Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice., Journal of virology, 89(19), 2015
  153. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones., The Journal of infection, 72(1), 2016
  154. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice., Antiviral therapy, 21(4), 2016
  155. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice., Virus research, 213, 2016
  156. Altered Serum Levels of Matrix Metalloproteinase-2, -9 in Response to Electroconvulsive Therapy for Mood Disorders., The international journal of neuropsychopharmacology, 19(9), 2016
  157. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection., Journal of gastroenterology, 51(11), 2016
  158. Pan-genotypic cell culture system for propagation of hepatitis C virus clinical isolates., Hepatology (Baltimore, Md.), 64(4), 2016
  159. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing., The Journal of infectious diseases, 214(11), 2016
  160. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology., The Journal of general virology, 98(5), 2017
  161. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy., Cellular and molecular gastroenterology and hepatology, 1(5), 2015
  162. Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus., PloS one, 12(3), 2017
  163. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus., Antimicrobial agents and chemotherapy, 61(6), 2017
  164. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of gastroenterology, 53(1), 2018
  165. Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy., Journal of gastroenterology, 53(1), 2018
  166. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice., Antimicrobial agents and chemotherapy, 61(9), 2017
  167. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease., Journal of gastroenterology, 53(2), 2018
  168. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients., Antiviral therapy, 23(3), 2018
  169. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice., Biochemical and biophysical research communications, 500(2), 2018
  170. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study., Antiviral therapy, 2018
  171. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure., The Journal of general virology, 99(8), 2018
  172. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients., Journal of viral hepatitis, 2018
  173. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25(12), 1555-1564, 201812
  174. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes, VIROLOGY, 525, 48-61, 201812
  175. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, ANTIVIRAL THERAPY, 23(3), 239-248, 2018
  176. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study, ANTIVIRAL THERAPY, 23(8), 639-646, 2018
  177. Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP, SCIENTIFIC REPORTS, 9, 20190611
  178. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54(7), 650-659, 201907
  179. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100(7), 1123-1131, 201907
  180. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy., J Med Virol., 92, 210-218, 202002
  181. Comparative study on the replication of HCV1b genome between wild-type and cell culture-adaptive mutant in regard to sensitivities against anti-HCV drugs., Microbiol Immunol., 64(4), 296-303, 202004
  182. Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1., J Infect Dis., 2020
  183. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib., Ther Adv Med Oncol.

Invited Lecture, Oral Presentation, Poster Presentation

  1. Detection and functional analysis of HBV-specific stem cell memory T cells (Tscm), EASL Congress 2023, 2023/06/21, Without Invitation, English, The European Association for the Study of the Liver, Vienna, Austria
  2. Detection and functional analysis of HBV-specific stem cell memory T cells (Tscm), 2022/11/13, Without Invitation, English
  3. Detection and functional analysis of HBV specific stem cell memory T cells (Tscm), The 72th AASLD Annual Meeting, 2021/11/12, Without Invitation, English, American Association for the Study of Liver Diseases, Digital Experience
  4. Host factors for Hepatitis B, Hiromi Chayama, US-Japan Hepatitis Panel Meeting, 2018/10/27, Without Invitation, English, The U.S.-Japan Cooperative Medical Sciences Program (USJCMSP), Kyoto, Japan
  5. Analysis of the effect on HBV by genome editing using CRISPR/Cas9 system, The 67th AASLD Annual Meeting, 2016/11/11, Without Invitation, English, American Association for the Study of Liver Diseases, Boston, USA
  6. Analysis of the effect on HBV life cycle by HBV genome editing using two different CRISPR/Cas9 systems, The 66th AASLD Annual Meeting, 2015/11/13, Without Invitation, English, American Association for the Study of Liver Diseases, San Francisco, USA

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI(Grant-in-Aid for Scientific Research (C)), 2022, 2024
  2. Research Program on Hepatitis, 2022//0/4/, 2023//0/3/
  3. The development of a novel therapy based on HBV-specific Tscm for the complete cure of chronic hepatitis B virus infection., 2022, 2025
  4. 2011
  5. KAKENHI, 2014, 2016
  6. KAKENHI, Analysis of hepatitis virus genomes using human hepatocytes transplanted chimeric mice and ultra-deep sequencing., 2012, 2013
  7. KAKENHI, Analysis of the relationship between IL28B SNP and HCV genome, 2010, 2011
  8. U.S.-Japan Cooperative Medical Sciences Program Collaborative Awards, 2018, Identification of host factors that support replication of hepatitis B virus for development of novel therapy, 2018, 2019
  9. Research Program on the challenges of Global Health issues , 2018/04/20, 2019/03/31